TY - JOUR
T1 - Inhibitory mechanisms of activated matrix metalloproteinase-9 on platelet activation
AU - Lee, Ye Ming
AU - Lee, Jie Jen
AU - Shen, Ming Yi
AU - Hsiao, George
AU - Sheu, Joen Rong
N1 - Funding Information:
This work was supported by grants from the National Science Council of Taiwan (NSC 90-2315-B-038-001-M61), Hsinchu Mackay Memorial Hospital (94002) Topnotch Stroke Research Center Grant, Ministry of Education.
PY - 2006/5/10
Y1 - 2006/5/10
N2 - The intracellular mechanisms underlying the signaling pathways of activated matrix metalloproteinase-9 (MMP-9) in platelets are not yet completely understood. Therefore, the aim of this study was to further examine the effects of activated MMP-9 in preventing platelet aggregation. In this study, activated MMP-9 time-dependently (3-60 min) inhibited platelet aggregation in washed human platelet suspensions stimulated by agonists. However, activated MMP-9 had no significant effect on the binding of FITC-triflavin to the platelet glycoprotein IIb/IIIa complex. Triflavin is a specific antagonist of the glycoprotein IIb/IIIa complex purified from snake venom. Moreover, activated MMP-9 (21 and 90 ng/ml) markedly decreased the fluorescence intensity of platelet membranes tagged with diphenylhexatriene. The thrombin-evoked increase in pHi was inhibited in the presence of activated MMP-9 (21 and 90 ng/ml). In addition, activated MMP-9 (21 and 90 ng/ml) markedly reduced the electron spin resonance (ESR) signal intensity of hydroxyl radicals in collagen (1 μg/ml)-activated platelets. These results indicate that the antiplatelet activity of activated MMP-9 may involve the following pathways: (1) activated MMP-9 may initially induce conformational changes in platelet membranes and hydroxyl radical formation, leading to inhibition of platelet aggregation; and (2) activated MMP-9 also inhibits the Na+/H+ exchanger, leading to reduced intracellular Ca2+ mobilization, and ultimately to inhibition of platelet aggregation. This study further provides new insights concerning the effects of activated MMP-9 on platelet aggregation.
AB - The intracellular mechanisms underlying the signaling pathways of activated matrix metalloproteinase-9 (MMP-9) in platelets are not yet completely understood. Therefore, the aim of this study was to further examine the effects of activated MMP-9 in preventing platelet aggregation. In this study, activated MMP-9 time-dependently (3-60 min) inhibited platelet aggregation in washed human platelet suspensions stimulated by agonists. However, activated MMP-9 had no significant effect on the binding of FITC-triflavin to the platelet glycoprotein IIb/IIIa complex. Triflavin is a specific antagonist of the glycoprotein IIb/IIIa complex purified from snake venom. Moreover, activated MMP-9 (21 and 90 ng/ml) markedly decreased the fluorescence intensity of platelet membranes tagged with diphenylhexatriene. The thrombin-evoked increase in pHi was inhibited in the presence of activated MMP-9 (21 and 90 ng/ml). In addition, activated MMP-9 (21 and 90 ng/ml) markedly reduced the electron spin resonance (ESR) signal intensity of hydroxyl radicals in collagen (1 μg/ml)-activated platelets. These results indicate that the antiplatelet activity of activated MMP-9 may involve the following pathways: (1) activated MMP-9 may initially induce conformational changes in platelet membranes and hydroxyl radical formation, leading to inhibition of platelet aggregation; and (2) activated MMP-9 also inhibits the Na+/H+ exchanger, leading to reduced intracellular Ca2+ mobilization, and ultimately to inhibition of platelet aggregation. This study further provides new insights concerning the effects of activated MMP-9 on platelet aggregation.
KW - Hydroxyl radical
KW - Matrix metalloproteinase-9
KW - Membrane fluidity
KW - Na/H exchanger
KW - Platelet aggregation
UR - http://www.scopus.com/inward/record.url?scp=33646164416&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646164416&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2006.03.031
DO - 10.1016/j.ejphar.2006.03.031
M3 - Article
C2 - 16624282
AN - SCOPUS:33646164416
SN - 0014-2999
VL - 537
SP - 52
EP - 58
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1-3
ER -